Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 79

1.

Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.

Alexandrescu DT, McClure R, Farzanmehr H, Dasanu CA.

J Clin Oncol. 2008 Aug 20;26(24):4047-8. doi: 10.1200/JCO.2008.18.3525. No abstract available.

PMID:
18711201
[PubMed - indexed for MEDLINE]
2.

Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.

Hiles JJ, Kolesar JM.

Am J Health Syst Pharm. 2008 Jan 15;65(2):123-31. doi: 10.2146/ajhp060661. Review.

PMID:
18192256
[PubMed - indexed for MEDLINE]
3.

[Cutaneous side effects of sorafenib and sunitinib].

Autier J, Mateus C, Wechsler J, Spatz A, Robert C.

Ann Dermatol Venereol. 2008 Feb;135(2):148-53; quiz 147, 154. doi: 10.1016/j.annder.2007.12.006. Epub 2008 Feb 13. Review. French. No abstract available.

PMID:
18342102
[PubMed - indexed for MEDLINE]
4.

Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.

Wong MK, Jarkowski A.

Pharmacotherapy. 2009 Apr;29(4):473-8. doi: 10.1592/phco.29.4.473. Review.

PMID:
19323623
[PubMed - indexed for MEDLINE]
5.

Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma.

Guevremont C, Alasker A, Karakiewicz PI.

Curr Opin Support Palliat Care. 2009 Sep;3(3):170-9. doi: 10.1097/SPC.0b013e32832e4681. Review.

PMID:
19528803
[PubMed - indexed for MEDLINE]
6.

Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma.

Bhojani N, Jeldres C, Patard JJ, Perrotte P, Suardi N, Hutterer G, Patenaude F, Oudard S, Karakiewicz PI.

Eur Urol. 2008 May;53(5):917-30. Epub 2007 Nov 26. Review.

PMID:
18054825
[PubMed - indexed for MEDLINE]
7.

Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.

Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G.

Nat Rev Clin Oncol. 2009 Apr;6(4):219-28. doi: 10.1038/nrclinonc.2009.4. Review.

PMID:
19333228
[PubMed - indexed for MEDLINE]
8.

[Managing the side effects of angiogenetic inhibitors in metastatic renal cell carcinoma].

Staehler M, Haseke N, Schöppler G, Stadler T, Heinemann G, Stief CG.

Urologe A. 2006 Oct;45(10):1333-42; quiz 1343. Review. German.

PMID:
17021905
[PubMed - indexed for MEDLINE]
9.

[Role of VEGFR-TKIs in the treatment of renal cell carcinoma].

Kondo T.

Nihon Jinzo Gakkai Shi. 2012;54(5):574-80. Review. Japanese. No abstract available.

PMID:
22991835
[PubMed - indexed for MEDLINE]
10.

[Efficacy of multikinase inhibitors in the treatment of advanced renal cell cancer. A snapshot].

Kuczyk M, Kruck S, Merseburger AS.

Urologe A. 2007 May;46(5):504-8, 510. Review. German.

PMID:
17437075
[PubMed - indexed for MEDLINE]
11.

CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.

Stein MN, Flaherty KT.

Clin Cancer Res. 2007 Jul 1;13(13):3765-70. Review. No abstract available.

PMID:
17606705
[PubMed - indexed for MEDLINE]
Free Article
12.

Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib.

Porta C, Paglino C, Imarisio I, Bonomi L.

Clin Exp Med. 2007 Dec;7(4):127-34. doi: 10.1007/s10238-007-0145-8. Epub 2008 Jan 11. Review.

PMID:
18188524
[PubMed - indexed for MEDLINE]
13.

Sorafenib.

Hasskarl J.

Recent Results Cancer Res. 2010;184:61-70. doi: 10.1007/978-3-642-01222-8_5. Review.

PMID:
20072831
[PubMed - indexed for MEDLINE]
14.

[Use of sorafenib in patients with hepatocellular or renal carcinoma].

Rosmorduc O, Chevreau C, Dielenseger P, Ederhy S, Goldwasser F, Grange JD, Mortier L, Neidhardt-Berard ME, Robert C, Scotté F, Seitz JF.

Gastroenterol Clin Biol. 2010 Mar;34(3):161-7. doi: 10.1016/j.gcb.2009.12.004. Epub 2010 Feb 23. Review. French.

PMID:
20181452
[PubMed - indexed for MEDLINE]
Free Article
15.

[Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib].

Wollenberg A, Staehler M, Eames T.

Hautarzt. 2010 Aug;61(8):662-7. doi: 10.1007/s00105-010-1942-7. Review. German.

PMID:
20631979
[PubMed - indexed for MEDLINE]
16.

Sorafenib in renal cell carcinoma.

Arranz JÁ, Climent MÁ, González-Larriba JL, León L, Maroto JP.

Crit Rev Oncol Hematol. 2011 Nov;80(2):314-22. doi: 10.1016/j.critrevonc.2011.01.008. Epub 2011 Mar 21. Review.

PMID:
21419641
[PubMed - indexed for MEDLINE]
17.

Sorafenib: delivering a targeted drug to the right targets.

Flaherty KT.

Expert Rev Anticancer Ther. 2007 May;7(5):617-26. Review.

PMID:
17492926
[PubMed - indexed for MEDLINE]
18.

Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.

Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J.

J Clin Oncol. 2010 May 1;28(13):2280-5. doi: 10.1200/JCO.2009.27.2757. Epub 2010 Mar 29. Review.

PMID:
20351323
[PubMed - indexed for MEDLINE]
19.

Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.

Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, Garbe C, Hauschild A, Puzanov I, Alexandrescu DT, Anderson RT, Wood L, Dutcher JP.

Oncologist. 2008 Sep;13(9):1001-11. doi: 10.1634/theoncologist.2008-0131. Epub 2008 Sep 8. Review.

PMID:
18779536
[PubMed - indexed for MEDLINE]
Free Article
20.

Targeted therapies for renal cell carcinoma: review of adverse event management strategies.

Eisen T, Sternberg CN, Robert C, Mulders P, Pyle L, Zbinden S, Izzedine H, Escudier B.

J Natl Cancer Inst. 2012 Jan 18;104(2):93-113. doi: 10.1093/jnci/djr511. Epub 2012 Jan 10. Review. Erratum in: J Natl Cancer Inst. 2012 Apr 18;104(8):638.

PMID:
22235142
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk